Biotech entity
pharma is the sole category represented across all 2 tracked stories. SURO Capital is most often covered alongside Blend Labs, which appears in 1 of these 2 stories. Their average consequence score of 5.5 runs below the beat's 6 for that window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. SURO Capital is most often covered alongside Blend Labs, which appears in 1 of these 2 stories. Their average consequence score of 5.5 runs below the beat's 6 for that window. Each story carries 3.5 original sources on average, compared with 4.3 for the broader beat in this window. This profile follows 2 Biotech stories mentioning SURO Capital across the period from March 12, 2026 to March 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 85 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SURO Capital. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen Downgrade
SABS and SSSS both receive Sell ratings from Wall Street Zen.
SAB-142 Clinical Progress
SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
Strategic Pivot
Company shifts focus from infectious diseases to immunology and chronic conditions.
Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.
Source: tickerreport.com · tickerreport.com
Shoulder Innovations reported a record Q4 2025 with $14.4 million in revenue, representing a 65% year-over-year increase. The company's growth is significantly outpacing legacy orthopedic incumbents, fueled by rapid surgeon adoption of its specialized arthroplasty platform.
SURO Capital is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
